[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Elana, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":78},{"warningLetters":4,"total":77},[5,31,56],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},2235,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2023-01-31T05:00:00Z\">01\u002F31\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-20T05:00:00Z\">01\u002F20\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fooo-elanders-643068-01202023\">OOO “Elanders” \u003C\u002Fa>","Center for Food Safety and Applied Nutrition","Seafood HACCP\u002FCGMP for Foods\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Genrih Pokotinsky\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO and Commercial Director \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>OOO “Elanders” \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Jaunciema Gatve 320\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Riga, Rigas rajons\u003C\u002Fspan>, \u003Cspan>LV-1015\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Latvia\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 20, 2023\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cbr>Reference #643068\u003C\u002Fp>\u003Cp>Dear Mr. Pokotinsky:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your seafood processing facility, OOO “Elanders”, located at Jaunciema Gatve 320, Riga, Rigas rajons, Latvia 1015 on July 11 - 12, 2022. During the inspection, we found that you had serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (21 CFR Part 123). At the conclusion of the inspection, the FDA investigator issued an FDA-483, Inspectional Observations, listing the deviations found at your facility. We received your response via email on August 15, 2022. Your response included two revised HACCP plans for ready-to-eat (RTE) refrigerated vacuum-packed cold smoked mackerel and RTE refrigerated salted herring fillets packed in marinade solution. However, our evaluation of the documents revealed that you continue to have serious concerns with your HACCP program as further described in this letter.\u003C\u002Fp>\u003Cp>In accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your RTE fish fillet products including vacuum-packed cold smoked mackerel and refrigerated salted herring fillets packed in marinade solution are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation, and the 4th Edition of the Fish and Fisheries Products Hazards &amp; Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>Your significant deviations are as follows:\u003C\u002Fp>\u003Cp>1. You must conduct or have conducted for you a hazard analysis for each kind of fish and fishery product that you produce to determine whether there are food safety hazards that are reasonably likely to occur and have a HACCP plan that, at a minimum, lists the food safety hazards that are reasonably likely to occur, to comply with 21 CFR 123.6(a) and (c)(1). A food safety hazard is defined in 21 CFR 123.3(f) as \"any biological, chemical, or physical property that may cause a food to be unsafe for human consumption.\" However, your firm’s revised HACCP plans for RTE refrigerated vacuum-packed cold smoked mackerel and RTE refrigerated salted herring fillets packed in marinade solution do not identify the food safety hazards of pathogen growth and toxin formation and allergens. Your plans correctly identify the hazards of histamine and \u003Cem>Clostridium botulinum\u003C\u002Fem>, however, since your products are intended to be consumed without further cooking, the growth of aerobic pathogens, including \u003Cem>Staphylococcus aureus\u003C\u002Fem> growth and toxin formation must also be prevented during processing activities. In addition, finfish are identified as a major food allergen. Controls must be included in your HACCP plan to assure that all allergenic ingredients are declared on product labels.\u003C\u002Fp>\u003Cp>2. You must conduct a hazard analysis to determine whether there are food safety hazards that are reasonably likely to occur and have a HACCP plan that, at a minimum, lists the critical control points, to comply with 21 CFR 123.6(a) and (c)(2). A critical control point is defined in 21 CFR 123.3(b) as a \"point, step, or procedure in a food process at which control can be applied and a food safety hazard can as a result be prevented, eliminated, or reduced to acceptable levels.\" However, your firm’s revised HACCP plan for RTE refrigerated vacuum-packed cold smoked mackerel does not identify a critical control point for \u003Cstrong>(b)(4)\u003C\u002Fstrong> to control the food safety hazard of \u003Cem>Clostridium botulinum\u003C\u002Fem> growth and toxin formation. During \u003Cstrong>(b)(4)\u003C\u002Fstrong>, it is critical that processors control the \u003Cstrong>(b)(4)\u003C\u002Fstrong> temperature to ensure temperatures do not exceed 32.2°C (90°F) to prevent the elimination of competing bacteria which can inhibit the growth of \u003Cem>Clostridium botulinum\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>3. You must have a HACCP plan that at minimum lists the critical limits that must be met, to comply with 21 CFR 123.6(c)(3). A critical limit is defined in 21 CFR 123.3(c) as the “the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard.” However, your firm’s revised HACCP plans for RTE refrigerated vacuum-packed cold smoked mackerel and RTE refrigerated salted herring fillets packed in marinade solution do not list adequate critical limits to control the food safety hazards of \u003Cem>C. botulinum\u003C\u002Fem> growth and toxin formation and scombrotoxin (histamine) formation at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> critical control points. Specifically,\u003C\u002Fp>\u003Cp>a. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> step lists a critical limit of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” that are inadequate to control histamine formation. FDA recommends monitoring ambient temperatures surrounding the fish to control histamine formation. When previously frozen fish are exposed to temperatures between 21°C and 25°C, safe exposure times should not exceed 12 hours. That limitation has not been included as a critical limit at this critical control point.\u003C\u002Fp>\u003Cp>AND\u003C\u002Fp>\u003Cp>b. Your Pickup warehouse and Storage critical control points list critical limits of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, respectively, which are inadequate to control the food safety hazard of scombrotoxin (histamine) formation. Your listed critical limits allow products to be held at up to \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C (\u003Cstrong>(b)(4)\u003C\u002Fstrong>°F). FDA recommends that the finished product be held at a cooler temperature of 40°F (4.4°C) or below.\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific things you are doing to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your revised HACCP plan or plans, five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products) to demonstrate implementation of the plan, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>If you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert #16-120. This alert can be found on FDA’s web site at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fimportalert_25.html.\u003C\u002Fp>\u003Cp>This letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the seafood HACCP regulation (21 CFR Part 123) and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\u003C\u002Fp>\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Giselle Jordan, Compliance Officer, Office of Compliance, Division of Enforcement, Food Adulteration and Assessment Branch (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding this letter, you may contact Giselle Jordan via email at: giselle.jordan@fda.hhs.gov. Please include reference #643068 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Ann M. Oxenham\u003Cbr>Director\u003Cbr>Office of Compliance\u003Cbr>Center for Food Safety and Applied Nutrition\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Genrih Pokotinsky\n\nRecipient Title\n\nCEO and Commercial Director\n\nOOO “Elanders”\n\nJaunciema Gatve 320\n\nRiga, Rigas rajons, LV-1015\n\nLatvia\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition\n\nUnited States\n\nJanuary 20, 2023\nWARNING LETTER\n\nReference #643068\nDear Mr. Pokotinsky:\nThe United States Food and Drug Administration (FDA) conducted an inspection of your seafood processing facility, OOO “Elanders”, located at Jaunciema Gatve 320, Riga, Rigas rajons, Latvia 1015 on July 11 - 12, 2022. During the inspection, we found that you had serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (21 CFR Part 123). At the conclusion of the inspection, the FDA investigator issued an FDA-483, Inspectional Observations, listing the deviations found at your facility. We received your response via email on August 15, 2022. Your response included two revised HACCP plans for ready-to-eat (RTE) refrigerated vacuum-packed cold smoked mackerel and RTE refrigerated salted herring fillets packed in marinade solution. However, our evaluation of the documents revealed that you continue to have serious concerns with your HACCP program as further described in this letter.\nIn accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your RTE fish fillet products including vacuum-packed cold smoked mackerel and refrigerated salted herring fillets packed in marinade solution are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation, and the 4th Edition of the Fish and Fisheries Products Hazards & Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\nYour significant deviations are as follows:\n1. You must conduct or have conducted for you a hazard analysis for each kind of fish and fishery product that you produce to determine whether there are food safety hazards that are reasonably likely to occur and have a HACCP plan that, at a minimum, lists the food safety hazards that are reasonably likely to occur, to comply with 21 CFR 123.6(a) and (c)(1). A food safety hazard is defined in 21 CFR 123.3(f) as \"any biological, chemical, or physical property that may cause a food to be unsafe for human consumption.\" However, your firm’s revised HACCP plans for RTE refrigerated vacuum-packed cold smoked mackerel and RTE refrigerated salted herring fillets packed in marinade solution do not identify the food safety hazards of pathogen growth and toxin formation and allergens. Your plans correctly identify the hazards of histamine and Clostridium botulinum, however, since your products are intended to be consumed without further cooking, the growth of aerobic pathogens, including Staphylococcus aureus growth and toxin formation must also be prevented during processing activities. In addition, finfish are identified as a major food allergen. Controls must be included in your HACCP plan to assure that all allergenic ingredients are declared on product labels.\n2. You must conduct a hazard analysis to determine whether there are food safety hazards that are reasonably likely to occur and have a HACCP plan that, at a minimum, lists the critical control points, to comply with 21 CFR 123.6(a) and (c)(2). A critical control point is defined in 21 CFR 123.3(b) as a \"point, step, or procedure in a food process at which control can be applied and a food safety hazard can as a result be prevented, eliminated, or reduced to acceptable levels.\" However, your firm’s revised HACCP plan for RTE refrigerated vacuum-packed cold smoked mackerel does not identify a critical control point for (b)(4) to control the food safety hazard of Clostridium botulinum growth and toxin formation. During (b)(4), it is critical that processors control the (b)(4) temperature to ensure temperatures do not exceed 32.2°C (90°F) to prevent the elimination of competing bacteria which can inhibit the growth of Clostridium botulinum.\n3. You must have a HACCP plan that at minimum lists the critical limits that must be met, to comply with 21 CFR 123.6(c)(3). A critical limit is defined in 21 CFR 123.3(c) as the “the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard.” However, your firm’s revised HACCP plans for RTE refrigerated vacuum-packed cold smoked mackerel and RTE refrigerated salted herring fillets packed in marinade solution do not list adequate critical limits to control the food safety hazards of C. botulinum growth and toxin formation and scombrotoxin (histamine) formation at the (b)(4) critical control points. Specifically,\na. Your (b)(4) step lists a critical limit of “(b)(4)” and “(b)(4)” that are inadequate to control histamine formation. FDA recommends monitoring ambient temperatures surrounding the fish to control histamine formation. When previously frozen fish are exposed to temperatures between 21°C and 25°C, safe exposure times should not exceed 12 hours. That limitation has not been included as a critical limit at this critical control point.\nAND\nb. Your Pickup warehouse and Storage critical control points list critical limits of “(b)(4)” and “(b)(4)”, respectively, which are inadequate to control the food safety hazard of scombrotoxin (histamine) formation. Your listed critical limits allow products to be held at up to (b)(4)°C ((b)(4)°F). FDA recommends that the finished product be held at a cooler temperature of 40°F (4.4°C) or below.\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific things you are doing to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your revised HACCP plan or plans, five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products) to demonstrate implementation of the plan, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nIf you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert #16-120. This alert can be found on FDA’s web site at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fimportalert_25.html.\nThis letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the seafood HACCP regulation (21 CFR Part 123) and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\nPlease send your reply to the Food and Drug Administration, Attention: Giselle Jordan, Compliance Officer, Office of Compliance, Division of Enforcement, Food Adulteration and Assessment Branch (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding this letter, you may contact Giselle Jordan via email at: giselle.jordan@fda.hhs.gov. Please include reference #643068 on any submissions and within the subject line of any email correspondence to the agency.\nSincerely,\n\u002FS\u002F\nAnn M. Oxenham\nDirector\nOffice of Compliance\nCenter for Food Safety and Applied Nutrition","OOO “Elanders”","ooo-elanders-643068-01202023","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fooo-elanders-643068-01202023","2026-10-26T08:09:38.482244+00:00","Warning Letter","Issued","2023-01-31","643068","Food & Beverages","Mr. Genrih Pokotinsky","2026-08-20T01:17:18.904+00:00","Via Express Delivery","2023-01-20",{"id":32,"raw":33,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":19,"letter_url":46,"updated_at":47,"action_type":22,"case_status":48,"posted_date":49,"marcs_cms_no":50,"product_type":51,"closeout_date":52,"issuing_office":37,"recipient_name":53,"body_fetched_at":54,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":55,"medical_device_id":19,"response_letter_date":19},1018,[34,35,36,37,38,13,39,13],"\u003Ctime datetime=\"2025-03-11T04:00:00Z\">03\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-01-28T05:00:00Z\">01\u002F28\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felanco-animal-health-695170-01282025\">Elanco Animal Health\u003C\u002Fa>","Center for Veterinary Medicine","False &amp; Misleading Claims\u002FMisbranded\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felanco-animal-health-695170-09112025\">\u003Ctime datetime=\"2025-09-19T04:00:00Z\">09\u002F19\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","False & Misleading Claims\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jeffrey Simmons\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Elanco Animal Health\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2500 Innovation Way\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Greenfield\u003C\u002Fspan>, \u003Cspan>IN\u003C\u002Fspan> \u003Cspan>46140\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 28, 2025\u003C\u002Fp>\u003Cp>Re: NADA 141-585, Zenrelia™ (ilunocitinib tablets)\u003C\u002Fp>\u003Cp>\u003Cstrong>CMS #: 695170\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Simmons:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) has reviewed your promotional communications for Zenrelia (ilunocitinib tablets) including your veterinarian product website,\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> the consumer directed website,\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> your Product Brochure and Itch Tracker,\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> which is linked on both websites, and a slide deck titled “Reach for Zen: New Relief for Dogs with Atopic Dermatitis\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>” and noted false or misleading claims and representations about the safety and effectiveness of Zenrelia. These promotional communications misbrand Zenrelia within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act). FD&amp;C Act section 502(a) [21 U.S.C. 352(a)] and section 502(n) [21 U.S.C. 352(n)]; see also section 201(n) [21 USC 321(n)]. It is a prohibited act to distribute a misbranded product in interstate commerce. FD&amp;C Act section 301(a) [21 U.S.C. 331(a)]. This violation is especially concerning from a public health perspective because the misleading promotional communications create a misleading impression regarding the safety and effectiveness of Zenrelia, which is a recently-approved veterinary drug in the Janus Kinase (JAK) inhibitor drug class.\u003C\u002Fp>\u003Cp>\u003Cstrong>Background\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Zenrelia is indicated for “control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.”\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Zenrelia’s FDA-approved Prescribing Information (PI) contains a boxed and bolded warning of the risk of “fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine” in dogs receiving Zenrelia. Therefore, the boxed warning states to discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination.\u003C\u002Fp>\u003Cp>The PI contains additional warning language including:\u003C\u002Fp>\u003Cp>“Dogs should be monitored for the development of infections because Zenrelia may increase susceptibility to opportunistic infections, including demodicosis, interdigital furunculosis, coccidiosis, and pneumonia, and exacerbation of subclinical or uncomplicated infections (see \u003Cstrong>Target Animal Safety\u003C\u002Fstrong> and \u003Cstrong>Adverse Reactions\u003C\u002Fstrong>).”\u003Cbr>…\u003Cbr>“Zenrelia may cause a progressive or persistently decreased hematocrit, hemoglobin, and\u002For red blood cell count without a corresponding increase in absolute reticulocyte count (see \u003Cstrong>Target Animal Safety\u003C\u002Fstrong>).”\u003Cbr>“New neoplastic conditions (benign and malignant) were observed in dogs treated with Zenrelia during clinical studies (see \u003Cstrong>Adverse Reactions\u003C\u002Fstrong>).”\u003C\u002Fp>\u003Cp>The PI contains additional adverse event, warning, precaution, and contraindication information.\u003Cem>\u003Cstrong>\u003Csup>6\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>False or Misleading Claims\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Prescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading in any particular. See FD&amp;C Act sections 502(a),(n) (21 U.S.C 352(a),(n)). The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in the light of its representations or material with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication. See FD&amp;C Act section 201(n) (21 U.S.C 321(n)) and 21 CFR 202.1(e)(5).\u003C\u002Fp>\u003Cp>\u003Cu>Omitted Information\u003C\u002Fu>\u003C\u002Fp>\u003Cp>The websites mentioned above and the Product Brochure and Itch tracker omit the phrase “from modified live virus vaccines” from the boxed warning found in the Important Safety Information (ISI) sections. The Vaccine Response Study in the Target Animal Safety section of the PI describes a dog that was administered Zenrelia that developed lethargy, depression, poor body condition, and weakness after receiving a modified live virus (MLV) vaccination and was subsequently euthanized. This dog was later diagnosed with adenoviral hepatitis and pancreatitis that “were concluded to be vaccine-induced, secondary to Zenrelia-induced immunosuppression.” Omitting the phrase “from modified live virus vaccines” in promotional material is misleading because the fatal vaccine-induced disease occurred after administration of a MLV DHPP vaccination,\u003Cem>\u003Cstrong>\u003Csup>7\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> a core vaccination for all dogs.\u003Cem>\u003Cstrong>\u003Csup>8\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Therefore, the phrase “from modified live virus vaccines” provides material facts that may be relevant to prescribing veterinarians and dog owners. &nbsp; &nbsp;\u003C\u002Fp>\u003Cp>In the ISI section of the consumer-directed website and on page one of the Product Brochure and Itch Tracker, the specific time period to withhold Zenrelia before and after vaccination is omitted (i.e., at least 28 days to 3 months prior to vaccination and at least 28 days after vaccination) and replaced with the phrase “for a time period before and after vaccination.” The specific time frame is also omitted from a 30-second video found on the veterinarian product website.\u003Cem>\u003Cstrong>\u003Csup>9\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> &nbsp;The phrase “for a time period before and after vaccination” is misleading because it does not provide necessary information to the pet owner. &nbsp;\u003C\u002Fp>\u003Cp>The Safety section of the Zenrelia veterinarian website contains only the statements “Read the entire package insert before using this drug, including the Boxed Warning” and “In clinical trials, the most observed adverse events were vomiting, diarrhea, and lethargy.” There is no mention of fatal vaccine-induced disease from MLV vaccines or inadequate immune response to any vaccines. We acknowledge that clicking on the box titled “Explore Zenrelia’s safety data” directs the reader to another webpage where more safety information is presented. However, this Safety section is also missing information about the risk of fatal vaccine-induced disease from MLV vaccines or inadequate immune response to any vaccines, as well as safety information from the Warnings section of the PI like monitoring for the development of infections, the risk of decreased hematocrit, hemoglobin, and\u002For red blood cell count, and the risk of new neoplastic conditions.\u003Cem>\u003Cstrong>\u003Csup>10\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>&nbsp;\u003C\u002Fp>\u003Cp>\u003Cu>Misrepresented Study Results\u003C\u002Fu>&nbsp;\u003C\u002Fp>\u003Cp>The veterinarian product website makes misleading claims about the results of the Vaccine Response Study. In the “Vaccinations FAQs” section of the website, under the question “What is vaccine-induced disease?” the response in part states “After the label was finalized, PCR testing confirmed this dog had Infectious Canine Hepatitis due to infection with canine adenovirus type 1 (CAV-1), which is genetically distinct from the strain of CAV-2 used in the MLV. Furthermore, this dog developed clinical signs of hepatitis (hematemesis) prior to receiving its first MLV. CAV-1 is highly contagious and difficult to kill with routine disinfectants; it is unknown how this dog became exposed or if it was a carrier prior to entering the bio-secure facility used for this study.” This claim is repeated on page 33 of the “Reach for Zen” slide deck. This information is in direct conflict with the PI and Freedom of Information (FOI) summary for Zenrelia, which concluded that the dog in the study had vaccine-induced adenoviral hepatitis and pancreatitis secondary to Zenrelia-induced immunosuppression.&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The Safety section of the Zenrelia veterinarian website also contains information about adverse reactions seen in the field studies conducted for approval,\u003Cem>\u003Cstrong>\u003Csup>11\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> accessible by clicking on the boxes titled “US atopic dermatitis study vs placebo” and “US allergic dermatitis study vs placebo”. However, the adverse reaction data found on the website is not consistent with the information found in the Zenrelia PI. For example, for the Control of Pruritus Associated with Allergic Dermatitis study, the PI states that diarrhea was reported in 26 (12.2%) dogs and urinary tract infections were reported in 13 (6.3%) Zenrelia treated dogs, while the Zenrelia website reports these numbers as 19 (9.2%) and 3 (1.5%), respectively. The adverse reaction data was reviewed and verified by the FDA as part of the approval process. The statements on the Zenrelia website are therefore false and misleading because they misrepresent the safety profile of Zenrelia.&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Additional Comments\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We offer the following additional comments about the promotion of Zenrelia:&nbsp;\u003C\u002Fp>\u003Cul>\u003Cli>Your product websites and Product Brochure state that there are “visible improvements in allergic itch from day one.” Neither effectiveness study (i.e., Control of Atopic Dermatitis or Control of Pruritus Associated with Allergic Dermatitis) supporting FDA approval assessed the speed of action of Zenrelia. According to the FOI summary, in the Control of Atopic Dermatitis study, treatment success\u003Cem>\u003Cstrong>\u003Csup>12\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> on Day 28 was identified as the primary effectiveness endpoint. Pruritus Visual Analog Scale (PVAS) scores were also assessed at other time points, but they were considered secondary endpoints. This study did demonstrate that the estimated mean PVAS scores were lower in the Zenrelia group compared to placebo on Day 1, however, this difference was relatively small, and it is unknown if it represented a clinically identifiable difference in pruritus in the treatment group compared to the placebo group. Therefore, it cannot be concluded that the difference in PVAS scores indicates that Zenrelia improved pruritus compared to placebo on Day 1. In the Control of Pruritus Associated with Allergic Dermatitis study, the primary effectiveness endpoint was treatment success\u003Cem>\u003Cstrong>\u003Csup>13\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> on at least 5 of the first 7 days of treatment. In this study, PVAS scores were assessed on Days 1 through 7, but the estimated mean PVAS score in the Zenrelia group was not lower than the placebo group until after Day 1, beginning on Day 2. &nbsp;\u003C\u002Fli>\u003Cli>Your product Detailer\u003Cem>\u003Cstrong>\u003Csup>14\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> makes the claim “77% of Zenrelia-treated dogs returned to normal versus 53% of Apoquel treated dogs.” The head-to-head study comparing treatment with Zenrelia to treatment with Apoquel showed that Zenrelia had similar efficacy as Apoquel on day 28, which was the primary effectiveness endpoint. The claim in the Detailer is based on PVAS scores on Day 112 of the study, which was a secondary endpoint. When multiple endpoints are tested statistically, the Type I error rate (the probability of erroneously concluding an effect when the truth is that there is no effect) may be inflated. Therefore, the p-values associated with the analyses of the multiple secondary endpoints should not be interpreted as evidence of statistically significant differences. We acknowledge you note with an asterisk that “PVAS &lt;2; P\u003Cu>&lt;\u003C\u002Fu>0.05. Secondary end point P values are not adjusted for multiple testing; therefore, caution should be exercised in interpretation.” However, this information is located in much smaller font at the bottom of the page and its inclusion in the Detailer does not mitigate the misleading impression made by the claim, which is presented prominently in large font in the center of the page. See 21 CFR 202.1(e)(7)(viii).\u003C\u002Fli>\u003Cli>Your product Detailer claims that “Results of multiple other studies demonstrate very similar safety profiles between Zenrelia and Apoquel.” The Zenrelia PI has a boxed warning regarding the risk of fatal vaccine-induced disease from modified live vaccines and inadequate immune response to any vaccine as well as additional warning language regarding the risk of progressive or persistently decreased hematocrit, hemoglobin, and\u002For red blood cell count without a corresponding increase in absolute reticulocyte count, while the Apoquel PI does not. Therefore, the claim of “similar safety profiles between Zenrelia and Apoquel” may be misleading.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion and Requested Response\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your websites, Product Brochure and Itch Tracker, and slide deck titled “Reach for Zen” misbrand Zenrelia within the meaning of the FD&amp;C Act. FD&amp;C Act section 502(a), (21 U.S.C. 352(a)); section 502(n) [21 U.S.C. 352(n)]; section 201(n) (21 U.S.C. 321(n));, and 21 CFR 202.1(e)(5). Introducing or delivering misbranded new animal drugs for introduction into interstate commerce violates section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)].\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal action, including without limitation, seizure, and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please submit a written response addressing the concerns described in this letter, listing all promotional communications for Zenrelia that contain representations like that described above, and explaining any plan for discontinuing use of such communications, or for ceasing distribution of Zenrelia. If you cannot complete the above requested actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete them.\u003C\u002Fp>\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\u003C\u002Fp>\u003Cp>Please direct your response to the undersigned at the Food and Drug Administration, Center for Veterinary Medicine, Division of Pharmacovigilance and Surveillance, 12225 Wilkins Ave, MPN II Room E436, Rockville, Maryland 20852. Please send a courtesy copy by email to CVMSurveillance@fda.hhs.gov. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter # 695170.\u003C\u002Fp>\u003Cp>If you have any questions, please contact Dr. Christopher Loss by email at christopher.loss@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Linda Walter-Grimm, DVM\u003Cbr>Director, Division of Pharmacovigilance and\u003Cbr>Surveillance\u003Cbr>Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>_____________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fmy.elanco.com\u002Fus\u002Fcampaign\u002Fzenrelia (last accessed on 1.27.25)\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fyourpetandyou.elanco.com\u002Fus\u002Four-products\u002Fzenrelia (last accessed on 1.27.25)\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-24-0697\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-24-1330 and submitted to the Drug Experience Report (DER) portal under cover of form 2301 on October 2, 2024.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> FDA-approved package insert (PI) for Zenrelia\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> The risk information reproduced in this letter is only for background information related to the letter’s subject matter and does not necessarily represent the risk information that should be included in any promotional communications.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> The DHPP vaccine contains canine distemper virus (CDV), canine adenovirus (CAV-2), canine parainfluenza (CPiV), and canine parvovirus (CPV).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> A Core Vaccination is recommended for all dogs irrespective of lifestyle, unless there is a specific medical reason not to vaccinate according to the American Animal Hospital Association.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-24-0930&nbsp;\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>10\u003C\u002Fstrong>\u003C\u002Fem> We recognize some of this information is found in the ISI section at the bottom of the main veterinarian website and linked webpage. However, due to the location and small size of the text, this information is not comparably noticeable or conspicuous compared to the benefit information. See 21 CFR 202.1(e)(7)(viii). &nbsp;\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>11\u003C\u002Fstrong>\u003C\u002Fem> The two field studies conducted for approval were the field study for Control of Atopic Dermatitis and the field study for Control of Pruritus Associated with Allergic Dermatitis. &nbsp;\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>12\u003C\u002Fstrong>\u003C\u002Fem> Treatment success for each dog was defined as at least a 50% reduction from baseline (Day 0) in owner-assessed PVAS score for pruritus or at least a 50% reduction from baseline in investigator assessed CADESI-4 (Canine Atopic Dermatitis Extent and Severity Index version 4) score for skin lesions.&nbsp;\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>13\u003C\u002Fstrong>\u003C\u002Fem> Treatment success for each dog was defined as at least a 50% reduction from baseline (Day 0) in owner-assessed PVAS score for pruritus on at least 5 out of the first 7 days of treatment&nbsp;\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>14\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-24-1164, submitted to the DER under cover of form 2301 on September 23, 2024.&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJeffrey Simmons\n\nRecipient Title\n\nPresident and CEO\n\nElanco Animal Health\n\n2500 Innovation Way\n\nGreenfield, IN 46140\n\nUnited States\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nJanuary 28, 2025\nRe: NADA 141-585, Zenrelia™ (ilunocitinib tablets)\nCMS #: 695170\nWARNING LETTER\nDear Mr. Simmons:\nThe U.S. Food and Drug Administration (FDA) has reviewed your promotional communications for Zenrelia (ilunocitinib tablets) including your veterinarian product website,1 the consumer directed website,2 your Product Brochure and Itch Tracker,3 which is linked on both websites, and a slide deck titled “Reach for Zen: New Relief for Dogs with Atopic Dermatitis4” and noted false or misleading claims and representations about the safety and effectiveness of Zenrelia. These promotional communications misbrand Zenrelia within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act). FD&C Act section 502(a) [21 U.S.C. 352(a)] and section 502(n) [21 U.S.C. 352(n)]; see also section 201(n) [21 USC 321(n)]. It is a prohibited act to distribute a misbranded product in interstate commerce. FD&C Act section 301(a) [21 U.S.C. 331(a)]. This violation is especially concerning from a public health perspective because the misleading promotional communications create a misleading impression regarding the safety and effectiveness of Zenrelia, which is a recently-approved veterinary drug in the Janus Kinase (JAK) inhibitor drug class.\nBackground\nZenrelia is indicated for “control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.”5\nZenrelia’s FDA-approved Prescribing Information (PI) contains a boxed and bolded warning of the risk of “fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine” in dogs receiving Zenrelia. Therefore, the boxed warning states to discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination.\nThe PI contains additional warning language including:\n“Dogs should be monitored for the development of infections because Zenrelia may increase susceptibility to opportunistic infections, including demodicosis, interdigital furunculosis, coccidiosis, and pneumonia, and exacerbation of subclinical or uncomplicated infections (see Target Animal Safety and Adverse Reactions).”\n…\n“Zenrelia may cause a progressive or persistently decreased hematocrit, hemoglobin, and\u002For red blood cell count without a corresponding increase in absolute reticulocyte count (see Target Animal Safety).”\n“New neoplastic conditions (benign and malignant) were observed in dogs treated with Zenrelia during clinical studies (see Adverse Reactions).”\nThe PI contains additional adverse event, warning, precaution, and contraindication information.6\nFalse or Misleading Claims\nPrescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading in any particular. See FD&C Act sections 502(a),(n) (21 U.S.C 352(a),(n)). The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in the light of its representations or material with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication. See FD&C Act section 201(n) (21 U.S.C 321(n)) and 21 CFR 202.1(e)(5).\nOmitted Information\nThe websites mentioned above and the Product Brochure and Itch tracker omit the phrase “from modified live virus vaccines” from the boxed warning found in the Important Safety Information (ISI) sections. The Vaccine Response Study in the Target Animal Safety section of the PI describes a dog that was administered Zenrelia that developed lethargy, depression, poor body condition, and weakness after receiving a modified live virus (MLV) vaccination and was subsequently euthanized. This dog was later diagnosed with adenoviral hepatitis and pancreatitis that “were concluded to be vaccine-induced, secondary to Zenrelia-induced immunosuppression.” Omitting the phrase “from modified live virus vaccines” in promotional material is misleading because the fatal vaccine-induced disease occurred after administration of a MLV DHPP vaccination,7 a core vaccination for all dogs.8\nTherefore, the phrase “from modified live virus vaccines” provides material facts that may be relevant to prescribing veterinarians and dog owners.\nIn the ISI section of the consumer-directed website and on page one of the Product Brochure and Itch Tracker, the specific time period to withhold Zenrelia before and after vaccination is omitted (i.e., at least 28 days to 3 months prior to vaccination and at least 28 days after vaccination) and replaced with the phrase “for a time period before and after vaccination.” The specific time frame is also omitted from a 30-second video found on the veterinarian product website.9 The phrase “for a time period before and after vaccination” is misleading because it does not provide necessary information to the pet owner.\nThe Safety section of the Zenrelia veterinarian website contains only the statements “Read the entire package insert before using this drug, including the Boxed Warning” and “In clinical trials, the most observed adverse events were vomiting, diarrhea, and lethargy.” There is no mention of fatal vaccine-induced disease from MLV vaccines or inadequate immune response to any vaccines. We acknowledge that clicking on the box titled “Explore Zenrelia’s safety data” directs the reader to another webpage where more safety information is presented. However, this Safety section is also missing information about the risk of fatal vaccine-induced disease from MLV vaccines or inadequate immune response to any vaccines, as well as safety information from the Warnings section of the PI like monitoring for the development of infections, the risk of decreased hematocrit, hemoglobin, and\u002For red blood cell count, and the risk of new neoplastic conditions.10\nMisrepresented Study Results\nThe veterinarian product website makes misleading claims about the results of the Vaccine Response Study. In the “Vaccinations FAQs” section of the website, under the question “What is vaccine-induced disease?” the response in part states “After the label was finalized, PCR testing confirmed this dog had Infectious Canine Hepatitis due to infection with canine adenovirus type 1 (CAV-1), which is genetically distinct from the strain of CAV-2 used in the MLV. Furthermore, this dog developed clinical signs of hepatitis (hematemesis) prior to receiving its first MLV. CAV-1 is highly contagious and difficult to kill with routine disinfectants; it is unknown how this dog became exposed or if it was a carrier prior to entering the bio-secure facility used for this study.” This claim is repeated on page 33 of the “Reach for Zen” slide deck. This information is in direct conflict with the PI and Freedom of Information (FOI) summary for Zenrelia, which concluded that the dog in the study had vaccine-induced adenoviral hepatitis and pancreatitis secondary to Zenrelia-induced immunosuppression.\n(b)(4)\nThe Safety section of the Zenrelia veterinarian website also contains information about adverse reactions seen in the field studies conducted for approval,11 accessible by clicking on the boxes titled “US atopic dermatitis study vs placebo” and “US allergic dermatitis study vs placebo”. However, the adverse reaction data found on the website is not consistent with the information found in the Zenrelia PI. For example, for the Control of Pruritus Associated with Allergic Dermatitis study, the PI states that diarrhea was reported in 26 (12.2%) dogs and urinary tract infections were reported in 13 (6.3%) Zenrelia treated dogs, while the Zenrelia website reports these numbers as 19 (9.2%) and 3 (1.5%), respectively. The adverse reaction data was reviewed and verified by the FDA as part of the approval process. The statements on the Zenrelia website are therefore false and misleading because they misrepresent the safety profile of Zenrelia.\nAdditional Comments\nWe offer the following additional comments about the promotion of Zenrelia:\nYour product websites and Product Brochure state that there are “visible improvements in allergic itch from day one.” Neither effectiveness study (i.e., Control of Atopic Dermatitis or Control of Pruritus Associated with Allergic Dermatitis) supporting FDA approval assessed the speed of action of Zenrelia. According to the FOI summary, in the Control of Atopic Dermatitis study, treatment success12 on Day 28 was identified as the primary effectiveness endpoint. Pruritus Visual Analog Scale (PVAS) scores were also assessed at other time points, but they were considered secondary endpoints. This study did demonstrate that the estimated mean PVAS scores were lower in the Zenrelia group compared to placebo on Day 1, however, this difference was relatively small, and it is unknown if it represented a clinically identifiable difference in pruritus in the treatment group compared to the placebo group. Therefore, it cannot be concluded that the difference in PVAS scores indicates that Zenrelia improved pruritus compared to placebo on Day 1. In the Control of Pruritus Associated with Allergic Dermatitis study, the primary effectiveness endpoint was treatment success13 on at least 5 of the first 7 days of treatment. In this study, PVAS scores were assessed on Days 1 through 7, but the estimated mean PVAS score in the Zenrelia group was not lower than the placebo group until after Day 1, beginning on Day 2.\nYour product Detailer14 makes the claim “77% of Zenrelia-treated dogs returned to normal versus 53% of Apoquel treated dogs.” The head-to-head study comparing treatment with Zenrelia to treatment with Apoquel showed that Zenrelia had similar efficacy as Apoquel on day 28, which was the primary effectiveness endpoint. The claim in the Detailer is based on PVAS scores on Day 112 of the study, which was a secondary endpoint. When multiple endpoints are tested statistically, the Type I error rate (the probability of erroneously concluding an effect when the truth is that there is no effect) may be inflated. Therefore, the p-values associated with the analyses of the multiple secondary endpoints should not be interpreted as evidence of statistically significant differences. We acknowledge you note with an asterisk that “PVAS \u003C2; P\u003C0.05. Secondary end point P values are not adjusted for multiple testing; therefore, caution should be exercised in interpretation.” However, this information is located in much smaller font at the bottom of the page and its inclusion in the Detailer does not mitigate the misleading impression made by the claim, which is presented prominently in large font in the center of the page. See 21 CFR 202.1(e)(7)(viii).\nYour product Detailer claims that “Results of multiple other studies demonstrate very similar safety profiles between Zenrelia and Apoquel.” The Zenrelia PI has a boxed warning regarding the risk of fatal vaccine-induced disease from modified live vaccines and inadequate immune response to any vaccine as well as additional warning language regarding the risk of progressive or persistently decreased hematocrit, hemoglobin, and\u002For red blood cell count without a corresponding increase in absolute reticulocyte count, while the Apoquel PI does not. Therefore, the claim of “similar safety profiles between Zenrelia and Apoquel” may be misleading.\nConclusion and Requested Response\nFor the reasons discussed above, your websites, Product Brochure and Itch Tracker, and slide deck titled “Reach for Zen” misbrand Zenrelia within the meaning of the FD&C Act. FD&C Act section 502(a), (21 U.S.C. 352(a)); section 502(n) [21 U.S.C. 352(n)]; section 201(n) (21 U.S.C. 321(n));, and 21 CFR 202.1(e)(5). Introducing or delivering misbranded new animal drugs for introduction into interstate commerce violates section 301(a) of the FD&C Act [21 U.S.C. 331(a)].\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal action, including without limitation, seizure, and injunction.\nWithin fifteen (15) working days of receipt of this letter, please submit a written response addressing the concerns described in this letter, listing all promotional communications for Zenrelia that contain representations like that described above, and explaining any plan for discontinuing use of such communications, or for ceasing distribution of Zenrelia. If you cannot complete the above requested actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete them.\nIf you believe that your products are not in violation of the FD&C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\nPlease direct your response to the undersigned at the Food and Drug Administration, Center for Veterinary Medicine, Division of Pharmacovigilance and Surveillance, 12225 Wilkins Ave, MPN II Room E436, Rockville, Maryland 20852. Please send a courtesy copy by email to CVMSurveillance@fda.hhs.gov. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter # 695170.\nIf you have any questions, please contact Dr. Christopher Loss by email at christopher.loss@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nLinda Walter-Grimm, DVM\nDirector, Division of Pharmacovigilance and\nSurveillance\nOffice of Surveillance and Compliance\nCenter for Veterinary Medicine\n_____________\n1 https:\u002F\u002Fmy.elanco.com\u002Fus\u002Fcampaign\u002Fzenrelia (last accessed on 1.27.25)\n2 https:\u002F\u002Fyourpetandyou.elanco.com\u002Fus\u002Four-products\u002Fzenrelia (last accessed on 1.27.25)\n3 Identified by Elanco as PM-US-24-0697\n4 Identified by Elanco as PM-US-24-1330 and submitted to the Drug Experience Report (DER) portal under cover of form 2301 on October 2, 2024.\n5 FDA-approved package insert (PI) for Zenrelia\n6 The risk information reproduced in this letter is only for background information related to the letter’s subject matter and does not necessarily represent the risk information that should be included in any promotional communications.\n7 The DHPP vaccine contains canine distemper virus (CDV), canine adenovirus (CAV-2), canine parainfluenza (CPiV), and canine parvovirus (CPV).\n8 A Core Vaccination is recommended for all dogs irrespective of lifestyle, unless there is a specific medical reason not to vaccinate according to the American Animal Hospital Association.\n9 Identified by Elanco as PM-US-24-0930\n10 We recognize some of this information is found in the ISI section at the bottom of the main veterinarian website and linked webpage. However, due to the location and small size of the text, this information is not comparably noticeable or conspicuous compared to the benefit information. See 21 CFR 202.1(e)(7)(viii).\n11 The two field studies conducted for approval were the field study for Control of Atopic Dermatitis and the field study for Control of Pruritus Associated with Allergic Dermatitis.\n12 Treatment success for each dog was defined as at least a 50% reduction from baseline (Day 0) in owner-assessed PVAS score for pruritus or at least a 50% reduction from baseline in investigator assessed CADESI-4 (Canine Atopic Dermatitis Extent and Severity Index version 4) score for skin lesions.\n13 Treatment success for each dog was defined as at least a 50% reduction from baseline (Day 0) in owner-assessed PVAS score for pruritus on at least 5 out of the first 7 days of treatment\n14 Identified by Elanco as PM-US-24-1164, submitted to the DER under cover of form 2301 on September 23, 2024.","Elanco Animal Health","elanco-animal-health-695170-01282025","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felanco-animal-health-695170-01282025","2026-10-26T08:08:32.23868+00:00","Closed Out","2025-03-11","695170","Animal & VeterinaryDrugs","2025-09-19","Jeffrey Simmons","2026-08-19T16:58:17.985+00:00","2025-01-28",{"id":57,"raw":58,"subject":40,"body_html":64,"body_text":65,"firm_name":66,"letter_id":67,"created_at":68,"fei_number":19,"letter_url":69,"updated_at":70,"action_type":22,"case_status":48,"posted_date":71,"marcs_cms_no":72,"product_type":73,"closeout_date":74,"issuing_office":37,"recipient_name":53,"body_fetched_at":75,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":76,"medical_device_id":19,"response_letter_date":19},334,[59,60,61,37,62,13,63,13],"\u003Ctime datetime=\"2026-02-17T05:00:00Z\">02\u002F17\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-01-08T05:00:00Z\">01\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felanco-animal-health-usa-710613-01082026\">Elanco Animal Health USA\u003C\u002Fa>","False &amp; Misleading Claims\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felanco-animal-health-usa-710613-08052026\">\u003Ctime datetime=\"2026-08-06T04:00:00Z\">08\u002F06\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jeffrey Simmons\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Elanco Animal Health USA\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2500 Innovation Way\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Greenfield\u003C\u002Fspan>, \u003Cspan>IN\u003C\u002Fspan> \u003Cspan>46140\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 8, 2026\u003C\u002Fp>\u003Cp>Re: NADA 141-550 Pradalex™ (pradofloxacin injection)\u003Cbr>\u003Cstrong>CMS #: 710613\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear: Mr. Simmons:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) has reviewed your promotional communications for Pradalex (pradofloxacin injection) including a print advertisement titled “Fast track recovery with Pradalex™,”\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> a detail aid titled “The Right Solution at the Right Time,”\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> a “Cattle technical manual”\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> linked on the Pradalex beef product website,\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> a promotional presentation titled “Pradalex (pradofloxacin injection) Cattle and Swine Product Overview,\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and a promotional video\u003Cem>\u003Cstrong>\u003Csup>6\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> featuring Elanco representatives discussing the presentation, and noted false or misleading claims and representations about the safety and effectiveness of this product. These promotional communications misbrand your product within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) section 502(a) [21 U.S.C. 352(a)], section 502(n) [21 U.S.C. 352(n)]; section 201(n) [21 U.S.C. 321(n)]; and 21 CFR 202.1(e)(5). It is a prohibited act to distribute a misbranded product in interstate commerce. Section 301(a) [21 U.S.C. 331(a)]. This violation is especially concerning because pradofloxacin is in the fluoroquinolone drug class and fluoroquinolones are considered critically important antimicrobials in human medicine.\u003Cem>\u003Cstrong>\u003Csup>7\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>Background\u003C\u002Fstrong>\u003Cem>\u003Cstrong>\u003Csup>8\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>According to the Indications section of the FDA-approved package insert:\u003C\u002Fp>\u003Cp>\u003Cstrong>In cattle:\u003C\u002Fstrong>\u003Cbr>Pradalex is indicated for the treatment of [Bovine Respiratory Disease] BRD associated with \u003Cem>Mannheimia haemolytica, Pasteurella multocida, Histophilus somni \u003C\u002Fem>and \u003Cem>Mycoplasma bovis\u003C\u002Fem> in cattle intended for slaughter (beef calves 2 months of age and older, growing beef steers, growing beef heifers, and beef bulls intended for slaughter), and in cattle intended for breeding less than 1 year of age (replacement beef and dairy heifers less than 1 year of age and beef and dairy bulls less than 1 year of age). Not for use in cattle intended for breeding 1 year of age and older (replacement beef and dairy heifers 1 year of age and older, beef and dairy bulls 1 year of age and older, and beef and dairy cows), beef calves less than 2 months of age, dairy calves, and veal calves.\u003C\u002Fp>\u003Cp>\u003Cstrong>In swine:\u003C\u002Fstrong>\u003Cbr>Pradalex is indicated for the treatment of [Swine Respiratory Disease] SRD associated with \u003Cem>Bordetella bronchiseptica, Glaesserella (Haemophilus) parasuis, Pasteurella multocida, Streptococcus suis, and Mycoplasma hyopneumoniae\u003C\u002Fem> in weaned swine intended for slaughter (nursery, growing, and finishing swine, boars intended for slaughter, barrows, gilts intended for slaughter, and sows intended for slaughter).\u003C\u002Fp>\u003Cp>Not for use in swine intended for breeding (boars intended for breeding, replacement gilts, and sows intended for breeding) and in nursing piglets.\u003C\u002Fp>\u003Cp>The package insert contains the following “CAUTION” statements: “Federal law prohibits the extra-label use of this drug in food-producing animals” and “To ensure responsible antimicrobial drug use, use of pradofloxacin should be limited to treatment of bovine respiratory disease (BRD) in cattle and treatment of swine respiratory disease (SRD) in swine only after consideration of other non-fluoroquinolone therapeutic options.”\u003C\u002Fp>\u003Cp>The Freedom of Information Summary for Pradalex explains that the caution statement about responsible antimicrobial drug use was added to “all labels, inserts and marketing materials” to reduce the risk to public health from development of fluoroquinolone resistance among foodborne \u003Cem>Campylobacter\u003C\u002Fem> and \u003Cem>Salmonella\u003C\u002Fem> originating from treated cattle and swine.\u003Cem>\u003Cstrong>\u003Csup>9 \u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>Specifically, inappropriate use of fluoroquinolones such as pradofloxacin contributes to antimicrobial resistance among organisms of human health concern, such as foodborne \u003Cem>Campylobacter\u003C\u002Fem> and \u003Cem>Salmonella\u003C\u002Fem>. Thus, use of pradofloxacin in food producing animals should be reserved for the treatment of clinical conditions that have responded poorly to other classes of antimicrobials.\u003C\u002Fp>\u003Cp>\u003Cstrong>False or Misleading Claims\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Prescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading in any particular (see FD&amp;C Act sections 502(a), (n) (21 U.S.C 352(a), (n)). The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication. See FD&amp;C Act section 201(n) (21 U.S.C 321(n)) and 21 CFR 202.1(e)(5).\u003C\u002Fp>\u003Cp>\u003Cstrong>First Pull Claims\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The detail aid titled “The Right Solution at the Right Time” contains a chart stating that the “Recommended Protocol” for Pradalex is “First-pull treatment.” Likewise, the Product Overview presentation titled “Pradalex (pradofloxacin injection) Cattle and Swine Product Overview” contains the following statement: “Pradalex is an ideal choice for first pull BRD and SRD treatment.” This claim is also repeated multiple times in the promotional video.\u003C\u002Fp>\u003Cp>“First pull” refers to the first time an animal is treated for a specific condition. However, the CAUTION statement on the package insert specifically states that pradofloxacin should only be used “after consideration of other non-fluoroquinolone therapeutic options.” As explained in the Human Food Safety section of the Freedom of Information Summary for Pradalex, “use of pradofloxacin in food producing animals should…be reserved for the treatment of clinical conditions which have responded poorly to other classes of antimicrobials.” Therefore, the claim that Pradalex is “Recommended” for “First-pull treatment” or an “ideal choice for a first pull” is false or misleading and causes the product to be misbranded.\u003C\u002Fp>\u003Cp>\u003Cstrong>All Relevant Pathogens Claims\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, the Product Overview presentation and associated video contain the statements:\u003C\u002Fp>\u003Cp>“Effective for the treatment of \u003Cu>all relevant BRD pathogens\u003C\u002Fu>.” [emphasis original]\u003Cbr>\u003Cem>and\u003C\u002Fem>\u003Cbr>“Effective for the treatment of \u003Cu>all relevant SRD pathogens\u003C\u002Fu>.” [emphasis original].\u003C\u002Fp>\u003Cp>The “all relevant BRD pathogens” claim is also repeated in a Cattle Technical Manual that is linked on the Pradalex cattle website. However, pradofloxacin treatment has not been shown to be effective for some pathogens that are relevant for BRD and SRD and therefore those pathogens are not part of the approved indication, including \u003Cem>Bibersteinia trehalosi, \u003C\u002Fem>which is a bacterial pathogen that may play a primary role in BRD\u003Cem>\u003Cstrong>\u003Csup>10, 11\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and \u003Cem>Actinobacillus pleuropneumoniae\u003C\u002Fem> (APP), which is considered a major pathogen in SRD. APP is described as a “primary bacterial pathogen” for SRD by a reference cited in the Product Overview presentation\u003Cem>\u003Cstrong>\u003Csup>12\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and is listed on a promotional flyer for SRD disseminated by Elanco.\u003Cem>\u003Cstrong>\u003Csup>13\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> This flyer even contains a table showing that pradofloxacin is not recommended for use for the treatment of APP. Therefore, stating that Pradalex is effective for “all relevant” pathogens for both BRD and SRD in the Product Overview presentation and video overstates the effectiveness of the drug and is a false or misleading claim.\u003C\u002Fp>\u003Cp>Further, these claims may promote extralabel use of Pradalex because it is only approved to treat BRD and SRD associated with certain pathogens, but these promotional communications suggest Pradalex is effective for all pathogens associated with BRD or SRD. As noted on the label, federal law prohibits the extra-label use of Pradalex in food producing animals. Advertising or promotion of extralabel uses in animals of approved new animal drugs is not permitted by the extralabel drug use regulations (see 21 CFR 530.4).\u003C\u002Fp>\u003Cp>\u003Cstrong>Comparative Claims\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The print advertisement titled “Fast track recovery with Pradalex” contains the statement “Treat respiratory disease with 2x the power in less than half the time” with a picture of a cow on a racetrack and a pig in a race car. This statement is false or misleading because it implies that Pradalex is effective against “respiratory disease” generally in cows and pigs. Pradalex is approved for the treatment of BRD and SRD associated with specific pathogens. There are other respiratory diseases in cattle and swine. Furthermore, it appears that this statement is making a claim about treatment times (“Treat… in less than half the time”) based on an in vitro measurement of bacterial kill rates against bovine strains of \u003Cem>Mannheimia haemolytica\u003C\u002Fem> and \u003Cem>Pasteurella multocida\u003C\u002Fem>. This statement cites Elanco data on file and a scientific article of an in vitro kill experiment measuring the rate and extent of bacterial killing by pradofloxacin against two BRD pathogens in comparison with seven other antimicrobials.\u003Cem>\u003Cstrong>\u003Csup>14\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Evidence of bacterial kill rates in a cell culture is not evidence of treatment times in cows and pigs. As noted in the scientific article itself, “In vitro measurements, as they are reported here, cannot be extrapolated to clinical outcomes…. Rapid reductions in viable cells may predict shorter courses of therapy; however, this would need confirmation in clinical trials investigating the length of therapy.”\u003Cem>\u003Cstrong>\u003Csup>15\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> In addition, it is unclear what “power” refers to in this statement. We also note that the study measured BRD pathogens, but the advertisement includes a picture of a pig.\u003C\u002Fp>\u003Cp>The Product Overview presentation and associated video also contain the following statements that are unclear and, therefore, may be misleading:\u003C\u002Fp>\u003Cp>“In cattle, Pradalex kills BRD bacteria with 3x the power in less than half the time.”\u003Cbr>and\u003Cbr>“Pradalex kills SRD bacteria with 2x the power in less than half the time.”\u003C\u002Fp>\u003Cp>These broad statements imply that the comparative “power” and speed of bacterial killing of Pradalex applies to all drugs approved for the same indications. However, for the BRD statement, the presentation and video do not indicate a direct comparison with any other antibiotic. For the SRD statement, the graph in the presentation and the explanation in the video only show a direct comparison between the plasma concentration of Pradalex and the plasma concentration of a single other drug, enrofloxacin. A similar statement on the product webpage for SRD\u003Cem>\u003Cstrong>\u003Csup>16\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>, “Pradalex is an SRD antibiotic treatment that reaches twice the concentration in a third of the time…” does not indicate a direct comparison with any other antibiotic. In addition, the meaning of the term “power” is unclear and could be interpreted to refer more broadly to the effectiveness of Pradalex or more specifically to the plasma concentration of Pradalex.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Response\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your promotional materials misbrand Pradalex within the meaning of the FD&amp;C Act. FD&amp;C Act section 502(a), [21 U.S.C. 352(a)]; section 502(n) [21 U.S.C. 352(n)]; section 201(n) [21 U.S.C. 321(n)]; and 21 CFR 202.1(e)(5). Introducing or delivering misbranded new animal drugs for introduction into interstate commerce violates section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)].\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal action, including without limitation, seizure, and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please submit a written response addressing the concerns described in this letter, listing all promotional communications for Pradalex that contain representations like that described above, and explaining any plan for discontinuing use of such communications, or for ceasing distribution of Pradalex. If you cannot complete the above requested actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete them.\u003C\u002Fp>\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\u003C\u002Fp>\u003Cp>Please direct your response to the undersigned at the Food and Drug Administration, Center for Veterinary Medicine, Division of Pharmacovigilance and Surveillance, 5001 Campus Drive, CPK1, College Park, MD, 20740. Please send a courtesy copy by email to CVMSurveillance@fda.hhs.gov. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter #710613.\u003C\u002Fp>\u003Cp>If you have any questions, please contact Dr. Christopher Loss by email at christopher.loss@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Linda Walter-Grimm, DVM\u003Cbr>Director, Division of Pharmacovigilance and\u003Cbr>Surveillance\u003Cbr>Office Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>_____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-25-2059 and submitted to the Drug Experience Reporting System (DERS) under cover of form 2301 on October 31, 2025.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-21-1022 and submitted to the DERS under cover of form 2301 on June 25, 2025.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-24-1012.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Pradalex (pradofloxacin injection) Beef Product Page last viewed on January 8, 2026.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-24-2153 and submitted to the DERS under cover of form 2301 on December 11, 2024.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-25-0047 and submitted to the DERS under cover of form 2301 on January 29, 2025.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> World Health Organization. Critically Important Antimicrobials for Human Medicine: 6th Revision 2018. See Draft Guidance for Industry #152 Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to their Microbiological Effects on Bacteria of Human Health Concern. Food and Drug Administration, Center of Veterinary Medicine, January 2023.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> This section does not include all the safety and risk information in the package insert for Pradalex and does not necessarily represent the risk information that should be included in the promotional communication(s) cited in this letter.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem> U.S. Food and Drug Administration, Center for Veterinary Medicine, April 9, 2024, Freedom of Information Summary, NADA 141-550 Pradalex (pradofloxacin injection) https:\u002F\u002Fanimaldrugsatfda.fda.gov\u002Fadafda\u002Fapp\u002Fsearch\u002Fpublic\u002Fdocument\u002FdownloadFoi\u002F15250 at 29.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>10\u003C\u002Fstrong>\u003C\u002Fem> Holschbach, C. L., Aulik, N., Poulsen, K., &amp; Ollivett, T. L. (2020). Prevalence and temporal trends in antimicrobial resistance of bovine respiratory disease pathogen isolates submitted to the Wisconsin Veterinary Diagnostic Laboratory: 2008–2017. Journal of Dairy Science, 103(10), 9464–9472. https:\u002F\u002Fdoi.org\u002F10.3168\u002Fjds.2019-17570\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>11\u003C\u002Fstrong>\u003C\u002Fem> Merck Veterinary Manual. (n.d.). Retrieved June 10, 2025, from https:\u002F\u002Fwww.merckvetmanual.com\u002Frespiratorysystem\u002Fbovine-respiratory-disease-complex\u002Foverview-of-bovine-respiratory-diseasecomplex#Etiology_v74932734\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>12\u003C\u002Fstrong>\u003C\u002Fem> Blondeau, J. M., &amp; Fitch, S. D. (2024). Comparison of the Minimum Inhibitory and Mutant Prevention Drug Concentrations for Pradofloxacin and 7 Other Antimicrobial Agents Tested Against Swine Isolates of Actinobacillus pleuropneumoniae and Pasteurella multocida. \u003Cem>Molecules (Basel, Switzerland)\u003C\u002Fem>, 29(22), Article 5448. https:\u002F\u002Fdoi.org\u002F10.3390\u002Fmolecules29225448\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>13\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-25-0197 and submitted to the DERS under cover of form 2301 on March 21, 2025.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>14\u003C\u002Fstrong>\u003C\u002Fem> Blondeau, J.M.; Fitch, S.D. Comparative In Vitro Killing by Pradofloxacin in Comparison to Ceftiofur, Enrofloxacin, Florfenicol, Marbofloxacin, Tildipirosin, Tilmicosin and Tulathromycin against Bovine Respiratory Bacterial Pathogens. Microorganisms 2024.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>15\u003C\u002Fstrong>\u003C\u002Fem> Id. at 11.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>16\u003C\u002Fstrong>\u003C\u002Fem> Pradalex (pradofloxacin injection) https:\u002F\u002Ffarmanimal.elanco.com\u002Fus\u002Fswine\u002Fproduct\u002Fpradalex last viewed January 8, 2026.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nAnimal & Veterinary\n\nRecipient:\n\nRecipient Name\n\nJeffrey Simmons\n\nRecipient Title\n\nPresident and CEO\n\nElanco Animal Health USA\n\n2500 Innovation Way\n\nGreenfield, IN 46140\n\nUnited States\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nJanuary 8, 2026\nRe: NADA 141-550 Pradalex™ (pradofloxacin injection)\nCMS #: 710613\nWARNING LETTER\nDear: Mr. Simmons:\nThe U.S. Food and Drug Administration (FDA) has reviewed your promotional communications for Pradalex (pradofloxacin injection) including a print advertisement titled “Fast track recovery with Pradalex™,”1 a detail aid titled “The Right Solution at the Right Time,”2 a “Cattle technical manual”3 linked on the Pradalex beef product website,4 a promotional presentation titled “Pradalex (pradofloxacin injection) Cattle and Swine Product Overview,5 and a promotional video6 featuring Elanco representatives discussing the presentation, and noted false or misleading claims and representations about the safety and effectiveness of this product. These promotional communications misbrand your product within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act) section 502(a) [21 U.S.C. 352(a)], section 502(n) [21 U.S.C. 352(n)]; section 201(n) [21 U.S.C. 321(n)]; and 21 CFR 202.1(e)(5). It is a prohibited act to distribute a misbranded product in interstate commerce. Section 301(a) [21 U.S.C. 331(a)]. This violation is especially concerning because pradofloxacin is in the fluoroquinolone drug class and fluoroquinolones are considered critically important antimicrobials in human medicine.7\nBackground8\nAccording to the Indications section of the FDA-approved package insert:\nIn cattle:\nPradalex is indicated for the treatment of [Bovine Respiratory Disease] BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis in cattle intended for slaughter (beef calves 2 months of age and older, growing beef steers, growing beef heifers, and beef bulls intended for slaughter), and in cattle intended for breeding less than 1 year of age (replacement beef and dairy heifers less than 1 year of age and beef and dairy bulls less than 1 year of age). Not for use in cattle intended for breeding 1 year of age and older (replacement beef and dairy heifers 1 year of age and older, beef and dairy bulls 1 year of age and older, and beef and dairy cows), beef calves less than 2 months of age, dairy calves, and veal calves.\nIn swine:\nPradalex is indicated for the treatment of [Swine Respiratory Disease] SRD associated with Bordetella bronchiseptica, Glaesserella (Haemophilus) parasuis, Pasteurella multocida, Streptococcus suis, and Mycoplasma hyopneumoniae in weaned swine intended for slaughter (nursery, growing, and finishing swine, boars intended for slaughter, barrows, gilts intended for slaughter, and sows intended for slaughter).\nNot for use in swine intended for breeding (boars intended for breeding, replacement gilts, and sows intended for breeding) and in nursing piglets.\nThe package insert contains the following “CAUTION” statements: “Federal law prohibits the extra-label use of this drug in food-producing animals” and “To ensure responsible antimicrobial drug use, use of pradofloxacin should be limited to treatment of bovine respiratory disease (BRD) in cattle and treatment of swine respiratory disease (SRD) in swine only after consideration of other non-fluoroquinolone therapeutic options.”\nThe Freedom of Information Summary for Pradalex explains that the caution statement about responsible antimicrobial drug use was added to “all labels, inserts and marketing materials” to reduce the risk to public health from development of fluoroquinolone resistance among foodborne Campylobacter and Salmonella originating from treated cattle and swine.9 Specifically, inappropriate use of fluoroquinolones such as pradofloxacin contributes to antimicrobial resistance among organisms of human health concern, such as foodborne Campylobacter and Salmonella. Thus, use of pradofloxacin in food producing animals should be reserved for the treatment of clinical conditions that have responded poorly to other classes of antimicrobials.\nFalse or Misleading Claims\nPrescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading in any particular (see FD&C Act sections 502(a), (n) (21 U.S.C 352(a), (n)). The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication. See FD&C Act section 201(n) (21 U.S.C 321(n)) and 21 CFR 202.1(e)(5).\nFirst Pull Claims\nThe detail aid titled “The Right Solution at the Right Time” contains a chart stating that the “Recommended Protocol” for Pradalex is “First-pull treatment.” Likewise, the Product Overview presentation titled “Pradalex (pradofloxacin injection) Cattle and Swine Product Overview” contains the following statement: “Pradalex is an ideal choice for first pull BRD and SRD treatment.” This claim is also repeated multiple times in the promotional video.\n“First pull” refers to the first time an animal is treated for a specific condition. However, the CAUTION statement on the package insert specifically states that pradofloxacin should only be used “after consideration of other non-fluoroquinolone therapeutic options.” As explained in the Human Food Safety section of the Freedom of Information Summary for Pradalex, “use of pradofloxacin in food producing animals should…be reserved for the treatment of clinical conditions which have responded poorly to other classes of antimicrobials.” Therefore, the claim that Pradalex is “Recommended” for “First-pull treatment” or an “ideal choice for a first pull” is false or misleading and causes the product to be misbranded.\nAll Relevant Pathogens Claims\nAdditionally, the Product Overview presentation and associated video contain the statements:\n“Effective for the treatment of all relevant BRD pathogens.” [emphasis original]\nand\n“Effective for the treatment of all relevant SRD pathogens.” [emphasis original].\nThe “all relevant BRD pathogens” claim is also repeated in a Cattle Technical Manual that is linked on the Pradalex cattle website. However, pradofloxacin treatment has not been shown to be effective for some pathogens that are relevant for BRD and SRD and therefore those pathogens are not part of the approved indication, including Bibersteinia trehalosi, which is a bacterial pathogen that may play a primary role in BRD10, 11 and Actinobacillus pleuropneumoniae (APP), which is considered a major pathogen in SRD. APP is described as a “primary bacterial pathogen” for SRD by a reference cited in the Product Overview presentation12 and is listed on a promotional flyer for SRD disseminated by Elanco.13 This flyer even contains a table showing that pradofloxacin is not recommended for use for the treatment of APP. Therefore, stating that Pradalex is effective for “all relevant” pathogens for both BRD and SRD in the Product Overview presentation and video overstates the effectiveness of the drug and is a false or misleading claim.\nFurther, these claims may promote extralabel use of Pradalex because it is only approved to treat BRD and SRD associated with certain pathogens, but these promotional communications suggest Pradalex is effective for all pathogens associated with BRD or SRD. As noted on the label, federal law prohibits the extra-label use of Pradalex in food producing animals. Advertising or promotion of extralabel uses in animals of approved new animal drugs is not permitted by the extralabel drug use regulations (see 21 CFR 530.4).\nComparative Claims\nThe print advertisement titled “Fast track recovery with Pradalex” contains the statement “Treat respiratory disease with 2x the power in less than half the time” with a picture of a cow on a racetrack and a pig in a race car. This statement is false or misleading because it implies that Pradalex is effective against “respiratory disease” generally in cows and pigs. Pradalex is approved for the treatment of BRD and SRD associated with specific pathogens. There are other respiratory diseases in cattle and swine. Furthermore, it appears that this statement is making a claim about treatment times (“Treat… in less than half the time”) based on an in vitro measurement of bacterial kill rates against bovine strains of Mannheimia haemolytica and Pasteurella multocida. This statement cites Elanco data on file and a scientific article of an in vitro kill experiment measuring the rate and extent of bacterial killing by pradofloxacin against two BRD pathogens in comparison with seven other antimicrobials.14 Evidence of bacterial kill rates in a cell culture is not evidence of treatment times in cows and pigs. As noted in the scientific article itself, “In vitro measurements, as they are reported here, cannot be extrapolated to clinical outcomes…. Rapid reductions in viable cells may predict shorter courses of therapy; however, this would need confirmation in clinical trials investigating the length of therapy.”15 In addition, it is unclear what “power” refers to in this statement. We also note that the study measured BRD pathogens, but the advertisement includes a picture of a pig.\nThe Product Overview presentation and associated video also contain the following statements that are unclear and, therefore, may be misleading:\n“In cattle, Pradalex kills BRD bacteria with 3x the power in less than half the time.”\nand\n“Pradalex kills SRD bacteria with 2x the power in less than half the time.”\nThese broad statements imply that the comparative “power” and speed of bacterial killing of Pradalex applies to all drugs approved for the same indications. However, for the BRD statement, the presentation and video do not indicate a direct comparison with any other antibiotic. For the SRD statement, the graph in the presentation and the explanation in the video only show a direct comparison between the plasma concentration of Pradalex and the plasma concentration of a single other drug, enrofloxacin. A similar statement on the product webpage for SRD16, “Pradalex is an SRD antibiotic treatment that reaches twice the concentration in a third of the time…” does not indicate a direct comparison with any other antibiotic. In addition, the meaning of the term “power” is unclear and could be interpreted to refer more broadly to the effectiveness of Pradalex or more specifically to the plasma concentration of Pradalex.\nConclusion and Requested Response\nFor the reasons discussed above, your promotional materials misbrand Pradalex within the meaning of the FD&C Act. FD&C Act section 502(a), [21 U.S.C. 352(a)]; section 502(n) [21 U.S.C. 352(n)]; section 201(n) [21 U.S.C. 321(n)]; and 21 CFR 202.1(e)(5). Introducing or delivering misbranded new animal drugs for introduction into interstate commerce violates section 301(a) of the FD&C Act [21 U.S.C. 331(a)].\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal action, including without limitation, seizure, and injunction.\nWithin fifteen (15) working days of receipt of this letter, please submit a written response addressing the concerns described in this letter, listing all promotional communications for Pradalex that contain representations like that described above, and explaining any plan for discontinuing use of such communications, or for ceasing distribution of Pradalex. If you cannot complete the above requested actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete them.\nIf you believe that your products are not in violation of the FD&C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\nPlease direct your response to the undersigned at the Food and Drug Administration, Center for Veterinary Medicine, Division of Pharmacovigilance and Surveillance, 5001 Campus Drive, CPK1, College Park, MD, 20740. Please send a courtesy copy by email to CVMSurveillance@fda.hhs.gov. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter #710613.\nIf you have any questions, please contact Dr. Christopher Loss by email at christopher.loss@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nLinda Walter-Grimm, DVM\nDirector, Division of Pharmacovigilance and\nSurveillance\nOffice Surveillance and Compliance\nCenter for Veterinary Medicine\n_____________________\n1 Identified by Elanco as PM-US-25-2059 and submitted to the Drug Experience Reporting System (DERS) under cover of form 2301 on October 31, 2025.\n2 Identified by Elanco as PM-US-21-1022 and submitted to the DERS under cover of form 2301 on June 25, 2025.\n3 Identified by Elanco as PM-US-24-1012.\n4 Pradalex (pradofloxacin injection) Beef Product Page last viewed on January 8, 2026.\n5 Identified by Elanco as PM-US-24-2153 and submitted to the DERS under cover of form 2301 on December 11, 2024.\n6 Identified by Elanco as PM-US-25-0047 and submitted to the DERS under cover of form 2301 on January 29, 2025.\n7 World Health Organization. Critically Important Antimicrobials for Human Medicine: 6th Revision 2018. See Draft Guidance for Industry #152 Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to their Microbiological Effects on Bacteria of Human Health Concern. Food and Drug Administration, Center of Veterinary Medicine, January 2023.\n8 This section does not include all the safety and risk information in the package insert for Pradalex and does not necessarily represent the risk information that should be included in the promotional communication(s) cited in this letter.\n9 U.S. Food and Drug Administration, Center for Veterinary Medicine, April 9, 2024, Freedom of Information Summary, NADA 141-550 Pradalex (pradofloxacin injection) https:\u002F\u002Fanimaldrugsatfda.fda.gov\u002Fadafda\u002Fapp\u002Fsearch\u002Fpublic\u002Fdocument\u002FdownloadFoi\u002F15250 at 29.\n10 Holschbach, C. L., Aulik, N., Poulsen, K., & Ollivett, T. L. (2020). Prevalence and temporal trends in antimicrobial resistance of bovine respiratory disease pathogen isolates submitted to the Wisconsin Veterinary Diagnostic Laboratory: 2008–2017. Journal of Dairy Science, 103(10), 9464–9472. https:\u002F\u002Fdoi.org\u002F10.3168\u002Fjds.2019-17570\n11 Merck Veterinary Manual. (n.d.). Retrieved June 10, 2025, from https:\u002F\u002Fwww.merckvetmanual.com\u002Frespiratorysystem\u002Fbovine-respiratory-disease-complex\u002Foverview-of-bovine-respiratory-diseasecomplex#Etiology_v74932734\n12 Blondeau, J. M., & Fitch, S. D. (2024). Comparison of the Minimum Inhibitory and Mutant Prevention Drug Concentrations for Pradofloxacin and 7 Other Antimicrobial Agents Tested Against Swine Isolates of Actinobacillus pleuropneumoniae and Pasteurella multocida. Molecules (Basel, Switzerland), 29(22), Article 5448. https:\u002F\u002Fdoi.org\u002F10.3390\u002Fmolecules29225448\n13 Identified by Elanco as PM-US-25-0197 and submitted to the DERS under cover of form 2301 on March 21, 2025.\n14 Blondeau, J.M.; Fitch, S.D. Comparative In Vitro Killing by Pradofloxacin in Comparison to Ceftiofur, Enrofloxacin, Florfenicol, Marbofloxacin, Tildipirosin, Tilmicosin and Tulathromycin against Bovine Respiratory Bacterial Pathogens. Microorganisms 2024.\n15 Id. at 11.\n16 Pradalex (pradofloxacin injection) https:\u002F\u002Ffarmanimal.elanco.com\u002Fus\u002Fswine\u002Fproduct\u002Fpradalex last viewed January 8, 2026.","Elanco Animal Health USA","elanco-animal-health-usa-710613-01082026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felanco-animal-health-usa-710613-01082026","2026-10-26T08:08:32.290643+00:00","2026-02-17","710613","Animal & Veterinary","2026-08-06","2026-08-19T04:57:49.046+00:00","2026-01-08",3,{"510k":79,"classification":80,"enforcement":81,"event":82,"event_backfill":83,"pma":84,"warning_letter":85},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]